What is NAD+ and Why It Declines With Age

Sophie Chabloz on July 30, 2026

What is NAD+ and Why It Declines With Age

By Sophie Chabloz | May 2026

This article explains what NAD+ is, what your cells use it for, why it declines with age, and what that decline does to your body.

In this article:

  • The chemistry of NAD+ in plain language

  • The three biological jobs that depend on it

  • The salvage pathway: how cells normally keep NAD+ topped up

  • Why NAD+ falls with age (the four real reasons)

  • What declining NAD+ does to you

  • How precursors fit into the picture

  • Where to go next

The chemistry of NAD+ in plain language

NAD+ stands for nicotinamide adenine dinucleotide. The "+" indicates its oxidised form, which carries an electron-shaped positive charge waiting to be neutralised. When NAD+ accepts a pair of electrons it becomes NADH, the reduced form. That continuous flip between NAD+ and NADH is the basic electron-shuttle service of metabolism (Cantó et al., 2015).

Structurally, the molecule is two nucleotides linked tail to tail. One nucleotide is built around adenine, the same base used in DNA and ATP. The other is built around nicotinamide, a small molecule derived from vitamin B3. The link between them is what makes NAD+ work, and it's also what gets cut every time an enzyme consumes NAD+.

Because that link gets cut, NAD+ is not a one-time gift. Your cells use it, lose it, and rebuild it constantly. In the most metabolically active tissues, your entire NAD+ pool turns over several times a day.

The three biological jobs that depend on it

Three classes of enzyme use NAD+, and each matters for a different reason.

Oxidoreductases (energy production)

The most basic role. Hundreds of enzymes that catalyse oxidation-reduction reactions need NAD+ as a cofactor. Glycolysis uses it. The citric acid cycle uses it. The electron transport chain depends on the NAD+/NADH ratio. Without an adequate NAD+ pool, ATP production falls and tissue energy declines (Imai & Guarente, 2014).

Sirtuins (cellular regulation)

The seven sirtuins (SIRT1 through SIRT7) are deacetylases that pull acetyl groups off other proteins. They influence everything from mitochondrial biogenesis (SIRT1, SIRT3) to genomic stability (SIRT6) to inflammatory tone. Every sirtuin reaction consumes NAD+ as a substrate, so when NAD+ is scarce, sirtuin activity drops and the regulatory effects ripple outward.

PARPs (DNA repair)

The poly(ADP-ribose) polymerase enzymes detect DNA damage and recruit repair machinery, which they do by transferring ADP-ribose units from NAD+ onto target proteins. PARP activity scales with damage. The more lesions your DNA carries, the more NAD+ gets pulled into repair, and the less is left for sirtuins or oxidoreductases. This is the cellular trade-off that turns chronic genomic stress into general metabolic decline.

The salvage pathway: how cells normally keep NAD+ topped up

You don't build NAD+ from scratch every time you need it - Your cells run a recycling loop called the salvage pathway.

The loop runs like this. Sirtuins, PARPs, and CD38 all break NAD+ down to nicotinamide. The enzyme NAMPT (nicotinamide phosphoribosyltransferase) then converts that nicotinamide into NMN. NMNAT enzymes convert NMN into fresh NAD+. Round and round.

NAMPT is the rate-limiting step. When its activity is high, the salvage loop spins fast and NAD+ stays plentiful. When its activity falls, the whole pool shrinks, because regeneration can't keep up with consumption.

This matters for two reasons. First, anything that boosts NAMPT (exercise, fasting, certain hormones) raises NAD+ indirectly. Second, feeding the pathway extra raw material (NMN, the substrate one step downstream of NAMPT) bypasses the bottleneck altogether. We cover this mechanism in detail at https://insights.avea-life.com/longevity/what-is-nmn-and-how-does-it-work/.

Why NAD+ falls with age (the four real reasons)

NAD+ levels in muscle, liver, and brain tissue drop roughly 50 percent between age 20 and 60 (Massudi et al., 2012). Four mechanisms drive that fall.

First, NAMPT activity declines. Older cells produce less of the salvage-pathway enzyme that recycles nicotinamide back into NAD+, so the recycling loop runs slower (Yoshino et al., 2018).

Second, CD38 expression rises. CD38 is one of the largest NAD+ consumers in your body, and it's expressed on senescent cells and chronically activated immune cells. As both populations expand with age, CD38-driven NAD+ destruction accelerates (Chini et al., 2020). Apigenin and a handful of other natural flavonoids inhibit CD38 directly.

Third, DNA damage accumulates and pulls more NAD+ into PARP repair. The genome that needed occasional touch-ups in your 20s needs constant attention by your 50s. In extreme cases, PARP activation can deplete cellular NAD+ by 80 percent.

Fourth, chronic low-grade inflammation (sometimes called "inflammaging") activates pathways that consume NAD+ faster than the salvage system can rebuild it. This is the connection between metabolic disease, autoimmunity, and accelerated cellular ageing.

The four mechanisms compound. CD38 expansion drives more NAD+ destruction, which slows DNA repair, which allows more damage, which activates more PARPs, which pulls NAD+ down further. Once that cycle is established, breaking it takes intervention.

What declining NAD+ does to you

The downstream consequences map onto familiar features of ageing. Lower mitochondrial output shows up as reduced exercise tolerance and slower recovery. Reduced sirtuin activity disrupts circadian rhythm and weakens the cellular stress responses that protect tissue. Reduced PARP capacity means slower DNA repair, which over years accumulates as more genomic damage and the senescent-cell burden that drives inflammation.

This is not a story of NAD+ alone causing ageing. It's a story of NAD+ being one of the cellular currencies whose devaluation makes everything else harder. Restoring it doesn't reverse ageing, but it lifts a limit that has been quietly bottlenecking dozens of biological processes. The hallmarks-of-ageing framework places NAD+ decline alongside genomic instability, mitochondrial dysfunction, and senescence as one of the interlocking drivers of cellular decline. We cover that broader picture at https://insights.avea-life.com/longevity/hallmarks-of-ageing/.

How precursors fit into the picture

If the salvage pathway is the recycling loop, NAD+ precursors are extra feedstock you add from outside. NMN (nicotinamide mononucleotide) sits one step downstream of the NAMPT bottleneck. NR (nicotinamide riboside) feeds in slightly upstream. Niacin and nicotinamide enter further upstream still and have been used for decades as vitamin supplements.

Of these, NMN has the strongest combination of mechanism, human trial data, and accumulated safety record. Across studies, oral NMN consistently raises blood and tissue NAD+ in middle-aged and older adults (Igarashi et al., 2022; Yoshino et al., 2021; Pencina et al., 2023). The effect is not dramatic, but it's reproducible across different doses, demographics, and outcome measures.

Quality matters more than dose. A 2021 analysis of NMN sold online found that more than half of products contained essentially zero NMN. The AVEA NMN supplement uses Longevir™, the only NMN currently manufactured in Europe, with enzymatic synthesis verified at greater than 99 percent purity. If you're going to invest in a precursor, the molecule needs to be present in the capsule.

Where to go next

This piece set up the biology. The next reads get more practical: "NMN supplements: how they work, who they're for" covers who benefits most from NMN, "NMN dosage: 250 mg vs 500 mg vs higher amounts" works through the dose-response question, and "How long does NMN take to raise NAD+ levels" sets out what to expect from a 30-, 60-, or 90-day protocol.

For the wider frame, "NAD+ Decline and How to Restore It" brings the lifestyle and CD38-inhibition angles into the same picture.

Related reading from AVEA insights

Leave a Reply

Your email address will not be published. Required fields are marked *